Clinical Trial Update: An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting [Phase 2]

View source ↗

Summary

This is a Phase 2 exploratory study evaluating tislelizumab in combination with chemotherapy for immuno-experienced patients with EGFR/ALK/ROS1-negative advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING